-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Solid Tumor Drug Details: PRS-342 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BOS-356 in Acne Vulgaris
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-356 in Acne Vulgaris report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-356 in Acne Vulgaris Drug Details: BOS-356 (GSK-3008356) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BO-112 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BO-112 in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BO-112 in Renal Cell Carcinoma Drug Details: BO-112 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BOS-475 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-475 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-475 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: BOS-475 (GSK-3183475)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: PRS-342...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BOS-172722 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-172722 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-172722 in Triple-Negative Breast Cancer (TNBC) Drug Details: BOS-172722 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BO-112 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BO-112 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BO-112 in Head And Neck Squamous Cell...
-
Product Insights
Khe Bo Mine
The Khe Bo Mine is a coal mine in Vietnam. It is currently in operation. Empower your strategies with our Khe Bo Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain...
-
Product Insights
Khe bo
Khe bo is a Hydro project located in Nghe An, Vietnam. The project is owned and developed by Viet Nam Power Development JSC. The project came online in 2013. Empower your strategies with our Khe bo report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be...
-
Product Insights
Bo-Karoo Diamond Mine
The Bo-Karoo Diamond Mine is a diamond mine in South Africa. It is currently in operation. Empower your strategies with our Bo-Karoo Diamond Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...